1. Treatment options for relapsed and refractory multiple myeloma
by Ajay K. Nooka, Efstathios Kastritis, Meletios A. Dimopoulos, and Sagar Lonial
Blood
Volume 125(20):
May 14, 2015
©2015 by American Society of Hematology

2. Treatment options for relapsed and refractory myeloma
Treatment options for relapsed and refractory myeloma. *NCCN category 1 recommendations; CFZ: carfilzomib; CPD: carfilzomib, pomalidomide and dexamethasone; CRD: carfilzomib, lenalidomide and dexamethasone; DCEP±V: dexamethasone, cyclophosphamide, etoposide...
Treatment options for relapsed and refractory myeloma. *NCCN category 1 recommendations; CFZ: carfilzomib; CPD: carfilzomib, pomalidomide and dexamethasone; CRD: carfilzomib, lenalidomide and dexamethasone; DCEP±V: dexamethasone, cyclophosphamide, etoposide, and cisplatin±bortezomib; DT-PACE±V: dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide±bortezomib; Pd: pomolidomide and dexamethasone; PFS: progression free survival; PLD: liposomal doxorubicin; PS: performance ststus; RCD: lenalidomide, cyclophosphamide and dexamethasone; RVD: lenalidomide, bortezomib and dexamethasone; SCT: autologous stem cell transplant; SCT2: second SCT; Td: thalidomide and dexamethasone; VCD: bortezomib, cyclophosphamide and dexamethasone; VTD: bortezomib, thalidomide and dexamethasone.
Ajay K. Nooka et al. Blood 2015;125:
©2015 by American Society of Hematology